



## ASX Company Announcement

### Sun Biomedical Completes Dimerix Bioscience Acquisition

**3 July 2015** - The Board of Sun Biomedical Limited is pleased to announce the completion of the transaction to acquire Dimerix Bioscience Limited as approved by shareholders at the shareholder meeting held on 30 June 2015.

Dr James Williams and Dr Sonia Poli have joined the company as Executive Chairman and Non-Executive Director respectively. The terms of Dr Williams' appointment are summarised below.

Mr Evan Cross and Mr Peter Webse have resigned as Non-Executive Directors effective immediately. Mr Peter Webse will continue to serve as a Company Secretary and Mr Howard Digby has transitioned to a Non-Executive Director role from his position as Executive Chairman. The Company is grateful to Mr Evans and Mr Webse for their services and contribution during their tenure and wishes them all the best in their future endeavours.

In addition, the Company has today issued the placement shares to sophisticated investor clients of Forrest Capital Pty Ltd, vendor shares, transaction options and corporate advisor options, the details of which are set out in the Appendix 3B lodged today.

Commenting on concluding the transaction, incoming Executive Chairman Dr Williams stated, "We are delighted to have successfully completed the merger of these companies, and associated capital raising. The group is now resourced and focused on accelerating the recruitment for the phase II clinical trial for chronic kidney disease, in addition to further developing other assets in the group's portfolio."

#### About Dimerix Bioscience

Dimerix Bioscience Limited is a public unlisted company, now a wholly owned subsidiary of Sun Biomedical, developing a new therapy for Chronic Kidney Disease that is currently recruiting for a Phase II trial being conducted in Melbourne. In addition Dimerix owns a patented drug discovery technology that is able to identify new applications of previously approved drugs and develop them for new medical indications with high unmet need. Since previously approved drugs have extensive prior clinical use, the clinical development pathway for Dimerix's therapies will be significantly shorter.

#### Executive Chairman appointment terms:

Salary: \$100,000 per annum, plus statutory superannuation

Term: Initial 12 months, thereafter 1 month notice period, other than for cause.

-end-

Howard Digby  
Executive Chairman (Outgoing)  
+61 434 987 750

James Williams  
Executive Chairman (Incoming)  
+61 409 050 519